Jim Robinson takes over the reins at Urovant; Carlos Campoy moves to CytomX
→ After nearly a year as president and COO at Paragon Biosciences, Jim Robinson has jumped to Urovant Sciences, where he will be president and CEO of the urology-focused biotech, succeeding founding CEO Keith Katkin. Robinson will continue as a member of Urovant’s board of directors. His previous stops include Alkermes as president and COO and a number of positions at Astellas and Schering-Plough Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.